Corbus Pharmaceuticals Stock Surges Ahead of Drug Data Readout

Dow Jones

Sep 12

Shares of Corbus Pharmaceuticals rallied after the company said it would host a webcast to discuss topline data for a study for an obesity treatment.

The stock was up 20% to $9.75 in late trading on Friday. At market close shares were roughly flat year to date.

Corbus said the webcast, scheduled for Monday at 8:00 a.m. EDT, will discuss data from a Phase 1b study of CRB-913 for the treatment of obesity, and include comments from an investigator for the study.

CRB-913 is a once-daily oral treatment. The company said it offers a new therapeutic option for obesity beyond GLP-1s and other incretin-targeting therapies.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2666957250"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666957250\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666957250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-12 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666957250","market":"sg","top_or_hot":-1,"title":"Corbus Pharmaceuticals Stock Surges Ahead of Drug Data Readout","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Corbus Pharmaceuticals rallied after the company said it would host a webcast to discuss topline data for a study for an obesity treatment. \n</p>\n<p>\n  The stock was up 20% to $9.75 in late trading on Friday. At market close shares were roughly flat year to date. \n</p>\n<p>\n  Corbus said the webcast, scheduled for Monday at 8:00 a.m. EDT, will discuss data from a Phase 1b study of CRB-913 for the treatment of obesity, and include comments from an investigator for the study. \n</p>\n<p>\n  CRB-913 is a once-daily oral treatment. The company said it offers a new therapeutic option for obesity beyond GLP-1s and other incretin-targeting therapies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corbus Pharmaceuticals Stock Surges Ahead of Drug Data Readout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorbus Pharmaceuticals Stock Surges Ahead of Drug Data Readout\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-12 05:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Corbus Pharmaceuticals rallied after the company said it would host a webcast to discuss topline data for a study for an obesity treatment. \n</p>\n<p>\n  The stock was up 20% to $9.75 in late trading on Friday. At market close shares were roughly flat year to date. \n</p>\n<p>\n  Corbus said the webcast, scheduled for Monday at 8:00 a.m. EDT, will discuss data from a Phase 1b study of CRB-913 for the treatment of obesity, and include comments from an investigator for the study. \n</p>\n<p>\n  CRB-913 is a once-daily oral treatment. The company said it offers a new therapeutic option for obesity beyond GLP-1s and other incretin-targeting therapies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2666957250","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666957250","pubTimestamp":1789162080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Corbus Pharmaceuticals rallied after the company said it would host a webcast to discuss topline data for a study for an obesity treatment.The stock was up 20% to $9.75 in late trading on Friday. At market close shares were roughly flat year to date.Corbus said the webcast, scheduled for Monday at 8:00 a.m. EDT, will discuss data from a Phase 1b study of CRB-913 for the treatment of obesity, and include comments from an investigator for the study.CRB-913 is a once-daily oral treatment. The company said it offers a new therapeutic option for obesity beyond GLP-1s and other incretin-targeting therapies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRBP":"Corbus Pharmaceuticals Holdings, Inc."},"translate_title":"Corbus Pharmaceuticals 股价在药品数据公布前飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBP":1.5},"content_text":"Shares of Corbus Pharmaceuticals rallied after the company said it would host a webcast to discuss topline data for a study for an obesity treatment. \n\n\n  The stock was up 20% to $9.75 in late trading on Friday. At market close shares were roughly flat year to date. \n\n\n  Corbus said the webcast, scheduled for Monday at 8:00 a.m. EDT, will discuss data from a Phase 1b study of CRB-913 for the treatment of obesity, and include comments from an investigator for the study. \n\n\n  CRB-913 is a once-daily oral treatment. The company said it offers a new therapeutic option for obesity beyond GLP-1s and other incretin-targeting therapies.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}